CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit
LARRY DELISLE BREAKS SILENCE 25 YEARS AFTER DRIVING KIDS INTO DETROIT RIVER - READ MORE

HR Notices From October 8

View Comments
(credit: istock) Technology Report
Read More

NanoBio Promotes David Peralta to CEO: NanoBio Corp. announced the promotion of David Peralta to CEO. Peralta, who previously served as the company’s COO and CFO, replaces James R. Baker Jr., M.D., who recently joined Merck & Co. as senior vice president, global vaccine franchise. As the scientific founder and inventor of NanoBio’s patented NanoStat technology platform, Dr. Baker will continue to serve on NanoBio’s board of directors. Peralta joined NanoBio in February 2006. During his tenure, Peralta has been directly responsible for the company’s business development, fundraising and finance-related activities, in addition to managing the company’s day-to-day operations. Previously, Peralta served as vice president and chief financial officer for Arbortext, Inc., a venture-backed enterprise software company, where he played a key role in accelerating the company’s growth, which ultimately led to Arbortext being acquired in 2005. Prior to joining Arbortext, Peralta was CFO of Mechanical Dynamics Inc. (NASDAQ:MDII), a publicly held software company, where he directed all finance and investor relations activities during the company’s initial public offering in 1996 and up through the sale of the company in 2002. NanoBio is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat technology platform. The company’s lead product candidates are treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratories are located in Ann Arbor.

Charles B. Shoemaker, Ph.D., Joins Synthetic Biologics’ Scientific Advisory Board: Synthetic Biologics Inc. (NYSE: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today that Charles B. Shoemaker joined the company’s Scientific Advisory Board. With more than 30 years of experience as a scientist in academia, government agencies and the biotechnology industry, Shoemaker currently serves as professor of biomedical sciences at Tufts University’s Cummings School of Veterinary Medicine. Shoemaker’s laboratory at the Cummings School at Tufts is developing treatments for both the prevention and cure of intoxication from a number of microbial toxins, primarily bioterror threat agents such as Botulinum neurotoxins as well as toxins from Clostridium difficile, E. coli, anthrax and ricin. In addition, he co-leads the Molecular Helminthology Laboratory at Tufts, in which research is directed to the development of therapeutics and vaccines for parasitic worm infections. Prior to joining Tufts, Shoemaker led the Animal Health Research Unit at the government-owned research company, AgResearch, in New Zealand. Previously Shoemaker was on the faculty and conducted his research at Harvard University. He began his career as one of the original scientists at the formation of Genetics Institute Inc., a highly successful biotechnology company in Boston that was later acquired by American Home Products and is now part of Pfizer. Shoemaker has published more than 100 peer-reviewed scientific publications, authored five patents and four pending patents in the biotechnology area, and is currently the principal investigator of multiple sponsored research projects being conducted at Tufts, including more than $1 million per year in NIH funding. Shoemaker earned his Ph.D. in biochemistry at the University of Iowa and was a postdoctoral fellow at the Massachusetts Institute of Technology in the laboratory of Nobel laureate, David Baltimore. He earned a B.S. in biochemistry from the University of New Hampshire.

Jeff Heng joins ReapSo as Director of Sales and Technology: Farmington Hills-based ReapSo LLC announced Tuesday that Jeff Heng will assume the role of director, sales and technology. Heng will oversee the company’s branding, sales, marketing, Web operations, mobile strategies and technology domains. Heng comes to ReapSo from EarlyIntern, where he was the Co-Founder building a smartphone app that is designed to improve and simplify the college internship process. He also recently served in an important executive advisory and organizational role at DECORativ, a fledgling home décor eCommerce website. Heng has worked on a variety of cutting edge mobile/web/software applications including crowdsourced apparel logistics, EHR/EMR (Electronic Health/Medical Records), and a small business crowdfunding platform. He is an adjunct faculty at the International Academy of Design and Technology, teaching UI/UX courses. Prior to that, Heng spent 4-years managing the branding, marketing, CRM, and web strategies at Elcometer. He is an active participant within the local Metro Detroit tech community, having chaired the Metro Detroit Netsuite Users Group and currently leading the Detroit Lean Startup and Metro Detroit Drupal Users Group. Heng holds a B.Sc. and an M.Sc. in Engineering and Computer Science from the University of Toledo, Ohio. ReapSo, launching in Q1 of 2013 in Michigan, features a revolutionary way in which consumers and brands interact in a mobile environment. The ReapSo mobile application will use direct loyalty and gamification engagements to help deliver value and entertainment for both businesses and consumers.

View Comments
blog comments powered by Disqus